Clinical trial
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent…
NCT00053144 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00053144 |
|---|---|
| Title | Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia |
| Official title | Irinotecan And Cytarabine In Refractory or Relapsed Acute Myeloid Leukemia And In Chronic Myelogenous Leukemia In Myeloid Blast Transformation: Efficacy And In Vitro Correlates |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, irinotecan hydrochloride |
| Start date | Nov 1, 1999 |
| Primary completion | Feb 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Jan 28, 2003 |
| Last update posted | Mar 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: